Methotrexate Morningside Healthcare

Methotrexate, the active ingredient in Methotrexate Morningside Healthcare, is an antimetabolite (folate antagonist) presented as an oral tablet for oral use. It is classified as a disease‑modifying antirheumatic drug and chemotherapy agent and treats rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma and ectopic pregnancy, with a well‑established safety profile when monitored appropriately.

GNH USA supplies Methotrexate Morningside Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance, and supports timely delivery to diverse markets.

Methotrexate is used in several disease categories, primarily targeting inflammatory and malignant conditions. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: improves skin lesions and decreases plaque formation. - Acute lymphoblastic leukemia: interferes with cancer cell proliferation as part of chemotherapy protocols. - Non‑Hodgkin lymphoma: contributes to tumor control in combination regimens. - Ectopic pregnancy: terminates trophoblastic tissue when surgical options are not chosen.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Mouth sores (stomatitis) - Elevated liver enzymes

Serious or Rare Side Effects: - Severe liver toxicity or hepatitis - Pulmonary fibrosis or interstitial pneumonitis - Bone marrow suppression leading to anemia, leukopenia or thrombocytopenia - Acute kidney injury or renal failure

When prescribing methotrexate, several safety considerations should be observed. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Monitor blood counts: check complete blood count regularly to detect marrow suppression. - Avoid use in pregnancy: drug is contraindicated and classified as pregnancy category X. - Provide folic acid supplementation: reduces risk of mucosal and hematologic toxicity. - Adjust dose in renal impairment: reduce dosage or increase monitoring in patients with reduced kidney function. - Store at room temperature: keep in the original container, protect from moisture and heat.

Methotrexate interacts with several medicines that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate serum levels and risk of toxicity. - Penicillins (e.g., ampicillin, amoxicillin): reduce renal clearance of methotrexate. - Sulfonamide antibiotics: may potentiate bone marrow suppression. - Live vaccines: risk of severe infection due to immunosuppression. - Proton pump inhibitors (e.g., omeprazole): can increase methotrexate exposure.

Moderate Interactions (Monitor Closely): - Trimethoprim‑sulfamethoxazole: may enhance hematologic toxicity. - Azathioprine: additive immunosuppressive effect. - Warfarin: methotrexate may increase anticoagulant effect. - Carbamazepine: may reduce methotrexate efficacy. - Phenytoin: may affect methotrexate metabolism.